Disc Medicine (IRON) Set to Announce Earnings on Thursday

Disc Medicine (NASDAQ:IRON) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.63) per share and revenue of $1.88 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

Disc Medicine Price Performance

Shares of Disc Medicine stock traded up $1.27 during trading on Tuesday, hitting $79.89. 104,789 shares of the stock traded hands, compared to its average volume of 659,636. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The stock has a market cap of $3.07 billion, a price-to-earnings ratio of -12.14 and a beta of 0.96. The firm’s fifty day moving average is $71.34 and its 200-day moving average is $70.79. Disc Medicine has a 52 week low of $40.00 and a 52 week high of $99.50.

Insider Activity

In related news, COO Jonathan Yu sold 8,796 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total transaction of $731,123.52. Following the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at $4,515,410.88. This trade represents a 13.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kevin Bitterman sold 25,519 shares of Disc Medicine stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $80.23, for a total value of $2,047,389.37. Following the completion of the transaction, the director directly owned 12,991 shares in the company, valued at $1,042,267.93. This trade represents a 66.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 173,046 shares of company stock valued at $13,591,034. Insiders own 3.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IRON. BMO Capital Markets upped their target price on Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a research note on Monday, October 19th. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of Disc Medicine in a research note on Thursday, September 10th. Cantor Fitzgerald boosted their price objective on shares of Disc Medicine from $125.00 to $170.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. Wells Fargo & Company boosted their price objective on shares of Disc Medicine from $86.00 to $124.00 and gave the stock an “overweight” rating in a report on Tuesday, October 20th. Finally, Morgan Stanley increased their target price on shares of Disc Medicine from $90.00 to $92.00 and gave the company an “overweight” rating in a report on Tuesday, October 20th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.